Equities

Ikena Oncology Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
IKNA:NMQ

Ikena Oncology Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.33
  • Today's Change0.02 / 1.53%
  • Shares traded8.10k
  • 1 Year change-18.40%
  • Beta0.5018
Data delayed at least 15 minutes, as of Jul 03 2025 18:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Ikena Oncology, Inc. is a clinical-stage, targeted oncology company. The Company is focused on developing differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance. Its lead program in the RAS pathway, IK-595, is a molecular glue designed to trap MEK and RAF in an inactive complex, more completely inhibiting RAS signals than existing inhibitors. IK-595’s ability to complex the RAFs, including CRAF prevents a signaling bypass mechanism that cancer cells employ to drive therapeutic resistance to other drugs in this class. IK-595 is being developed as an oral therapy and evaluated in a Phase I clinical trial in RAS and RAF mutant cancers.

  • Revenue in USD (TTM)0.00
  • Net income in USD-41.71m
  • Incorporated2016
  • Employees9.00
  • Location
    Ikena Oncology Inc645 Summer Street, Suite 101BOSTON 02210United StatesUSA
  • Phone+1 (857) 273-8343
  • Fax+1 (302) 655-5049
  • Websitehttps://www.ikenaoncology.com
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
IKNA:NMQ since
announced
Transaction
value
Inmagene BiopharmaceuticalsAnnounced23 Dec 202423 Dec 2024Announced-14.19%--
Data delayed at least 15 minutes, as of Jul 03 2025 18:00 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Serina Therapeutics Inc65.00k-939.00k59.21m12.00--34.68--910.87-0.0516-0.05160.00680.17130.0074----5,416.67-11.53-188.54-153.87-------1,560.00-7,513.03----0.00---60.56-49.6424.74---49.05--
PDS Biotechnology Corp0.00-35.50m60.79m24.00--2.70-----0.94-0.940.000.49210.00----0.00-61.18-57.93-85.84-68.38-----------16.020.4588------12.42------
Medicinova Inc0.00-11.16m61.31m13.00--1.23-----0.2275-0.22750.001.020.00----0.00-19.35-15.56-20.16-16.17-------1,144.98----0.00---100.00---28.91---39.68--
Repare Therapeutics Inc1.07m-127.89m61.76m129.00--0.4937--57.56-3.01-3.010.02532.920.0053--0.08338,317.83-62.83-24.80-71.53-28.19-----11,919.29-150.65----0.00--4.58--9.71------
PMV Pharmaceuticals Inc0.00-60.88m61.82m63.00--0.3862-----1.18-1.180.003.080.00----0.00-29.88-21.46-31.57-22.32------------0.00------14.87--43.14--
Metagenomi Inc45.26m-77.95m62.43m176.00--0.2936--1.38-2.11-2.111.235.690.1269--29.26224,074.30-21.86---25.87-------172.21------0.00--16.84---14.36------
Clearside Biomedical Inc3.76m-30.81m63.12m32.00------16.77-0.4077-0.40770.0498-0.59410.1259--4.89117,625.00-103.03-67.79-126.15-84.9489.45---818.57-241.58---------79.77-5.20-5.75--108.16--
Alto Neuroscience Inc0.00-63.18m63.62m76.00--0.4574-----2.35-2.350.005.140.00----0.00-33.09---34.47--------------0.132-------69.21------
Ikena Oncology Inc0.00-41.71m64.18m9.00--0.5428-----0.8643-0.86430.002.450.00----0.00-27.47-29.58-29.30-33.67-------407.25----0.00---100.00--27.77------
Sutro Biopharma Inc66.43m-245.22m64.46m269.00------0.9703-2.98-2.980.808-0.3060.1833--2.96214,303.20-67.66-31.36-95.74-37.63-----369.11-152.29---------59.647.74-112.99---2.30--
Connect Biopharma Holdings Ltd (ADR)26.03m-17.21m64.97m62.00------2.50-0.3109-0.31090.4701--------419,887.10---61.12---66.78-----66.10-1,963.00----0.00------74.84--37.04--
Adaptimmune Therapeutics PLC - ADR179.64m-69.90m66.26m506.00------0.3689-0.2765-0.27650.6986-0.14520.8635--28.10355,017.80-33.60-36.56-46.82-43.795.32---38.91-231.641.79------195.34175.4937.81---2.42--
INmune Bio Inc50.00k-40.80m67.26m22.00--1.96--1,345.21-1.95-1.950.00241.290.0012--0.02442,272.73-96.41-45.54-137.69-52.16-----81,592.00-19,298.45---96.120.00---90.97---40.24------
RetinalGenix Technologies Inc0.00-2.76m67.61m0.00---------0.152-0.1520.00-0.090.00-------8,846.15-14,417.91---------------727.82---------106.65------
Pyxis Oncology Inc0.00-95.23m68.14m44.00--0.6575-----1.56-1.560.001.670.00----0.00-53.49-47.22-58.15-53.45-------2,233.63----0.0008-------4.80------
Anebulo Pharmaceuticals Inc0.00-7.69m69.02m2.00--5.13-----0.2676-0.26760.000.32770.00----0.00-76.88---83.37-------------34.490.00------30.09------
Data as of Jul 03 2025. Currency figures normalised to Ikena Oncology Inc's reporting currency: US Dollar USD

Institutional shareholders

37.26%Per cent of shares held by top holders
HolderShares% Held
BML Capital Management LLCas of 16 Jun 20254.03m9.62%
BVF Partners LPas of 31 Mar 20254.01m9.57%
Deep Track Capital LPas of 31 Mar 20252.52m6.01%
OrbiMed Advisors LLCas of 30 Apr 20251.63m3.88%
The Vanguard Group, Inc.as of 31 Mar 20251.38m3.29%
Adage Capital Management LPas of 31 Mar 2025800.00k1.91%
BlackRock Fund Advisorsas of 31 Mar 2025345.36k0.82%
Geode Capital Management LLCas of 31 Mar 2025317.09k0.76%
Peapod Lane Capital LLCas of 31 Mar 2025296.44k0.71%
Renaissance Technologies LLCas of 31 Mar 2025294.49k0.70%
More ▼
Data from 31 Mar 2025 - 30 Apr 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.